Correction to: Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-3774
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study ; volume:116 ; number:6 ; day:8 ; month:11 ; year:2022 ; pages:976-977 ; date:12.2022
International journal of hematology ; 116, Heft 6 (8.11.2022), 976-977, 12.2022
- Urheber
-
Kawabata, Hiroshi
Tamura, Takeshi
Tamai, Soichiro
Fujibayashi, Akiko
Sugimura, Motoi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12185-022-03485-8
- URN
-
urn:nbn:de:101:1-2023012909105815687822
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kawabata, Hiroshi
- Tamura, Takeshi
- Tamai, Soichiro
- Fujibayashi, Akiko
- Sugimura, Motoi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
Intravenous ferric carboxymaltose for anaemia in pregnancy
Intravenous ferric derisomaltose for iron-deficiency anemia associated with gastrointestinal diseases: a single-arm, randomized, uncontrolled, open-label study
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China
Treatment of anemia of inflammation with intravenous ferric carboxymaltose in a murine anemia model using heat-killed brucella abortus
Cost-effectiveness of ferric citrate hydrate in patients with iron deficiency anemia
Efficacy of Intravenous Ferric Carboxymaltose in Heart Failure Patients with Iron Deficiency Anemia: A Meta-analysis of 6271 Patients
Ferric pyrophosphate citrate: interactions with transferrin
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
Intravenous ferric carboxymaltose for anaemia in pregnancy
Intravenous ferric derisomaltose for iron-deficiency anemia associated with gastrointestinal diseases: a single-arm, randomized, uncontrolled, open-label study
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China
Treatment of anemia of inflammation with intravenous ferric carboxymaltose in a murine anemia model using heat-killed brucella abortus
Cost-effectiveness of ferric citrate hydrate in patients with iron deficiency anemia
Efficacy of Intravenous Ferric Carboxymaltose in Heart Failure Patients with Iron Deficiency Anemia: A Meta-analysis of 6271 Patients
Ferric pyrophosphate citrate: interactions with transferrin
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
Intravenous ferric carboxymaltose for anaemia in pregnancy
Intravenous ferric derisomaltose for iron-deficiency anemia associated with gastrointestinal diseases: a single-arm, randomized, uncontrolled, open-label study
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China
Treatment of anemia of inflammation with intravenous ferric carboxymaltose in a murine anemia model using heat-killed brucella abortus
Cost-effectiveness of ferric citrate hydrate in patients with iron deficiency anemia
Efficacy of Intravenous Ferric Carboxymaltose in Heart Failure Patients with Iron Deficiency Anemia: A Meta-analysis of 6271 Patients